Filtern
Volltext vorhanden
- ja (26)
Gehört zur Bibliographie
- ja (26)
Erscheinungsjahr
Dokumenttyp
Schlagworte
- ADHD (6)
- depression (4)
- bipolar disorder (3)
- pregnancy (3)
- BDNF (2)
- Bipolar disorder (2)
- antidepressant (2)
- anxiety (2)
- attention (2)
- hyperactivity (2)
- impulsivity (2)
- lactation (2)
- mental disorders (2)
- mental health (2)
- peripartum (2)
- polygenic risk score (2)
- systematic review (2)
- Abelson helper integration-1 (AHI1) (1)
- Adult (1)
- Aggression (1)
- Alzheimers disease (1)
- Antisocial behavior (1)
- Arbeitsg (1)
- Association (1)
- Aufmerksamkeits-Defizit-Syndrom (1)
- Biomarke (1)
- C-reactive protein (1)
- COGITAT-Box (1)
- COVID-19 (1)
- Conduct disorder (1)
- Covid-19 (1)
- Cytokines (1)
- Deficit/hyperactivity disorder (1)
- Depression (1)
- Diagnostic approach (1)
- Dopamine Transporter (1)
- Dopaminstoffwechsel (1)
- Dopamintransporter (1)
- EBM (1)
- Elevated Plus Maze (1)
- Fibromyalgia syndrome (1)
- GHQ-28 (1)
- GRN (1)
- GWAS (1)
- Gene (1)
- Genotype (1)
- Inflammatio (1)
- Large multicenter ADHD (1)
- Maintenance treatment (1)
- Mania (1)
- Monopolar depression (1)
- Nesplora Aquarium (1)
- Nitric oxide (1)
- Nitric oxide synthase (1)
- Opioid receptor (1)
- PARK2 (1)
- Polarity index (1)
- Predominant polarity (1)
- Qb-Test (1)
- Rating scale (1)
- Schizophrenie (1)
- Serotonin (1)
- Serotonine transporter (1)
- Serotonintransporter (1)
- Skin biopsy (1)
- Stickstoffmonoxid (1)
- Stickstoffmonoxid-Synthase (1)
- Stickstoffoxidsynthase (1)
- Susceptibility loci (1)
- UPPS (1)
- accidents (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- age (1)
- antidepressants (1)
- anxious depression (1)
- association (1)
- astrocytes (1)
- attention deficit hyperactivity disorder (1)
- breast cancer (1)
- ceramides (1)
- child development (1)
- clinical practice guideline (1)
- cognitive deficits (1)
- cohort studies (1)
- continuous performance test (1)
- cortical activation (1)
- cross-sectional studies (1)
- cross-sectional study (1)
- dementia (1)
- depressive disorder (1)
- disease modelling (1)
- early recognition (1)
- endocannabinoids (1)
- fNIRS (1)
- families (1)
- family caregivers (1)
- fibromyalgia syndrome (1)
- frontotemporal lobar degeneration (1)
- gene (1)
- geneexpression (1)
- genetic phenotypes (1)
- genome-wide association (1)
- glia (1)
- hiPSC (1)
- illness (1)
- incidence (1)
- informal caregiving (1)
- linkage (1)
- lithium (1)
- longitudinal studies (1)
- major depression (1)
- mapping susceptibility genes (1)
- maternal (1)
- mechanismofaction (1)
- mental illness (1)
- mitochondria (1)
- monoamine transporters (1)
- mood disorders (1)
- morality (1)
- mutation (1)
- near-infrared spectroscopy (1)
- neuropsychology (1)
- nitricoxidesynthase (1)
- observer agreement (1)
- onset (1)
- pain (1)
- paternal (1)
- people (1)
- pharmacotherapy (1)
- physical health (1)
- population-based studies (1)
- postnatal depression (1)
- prefrontal cortex (1)
- prevalence (1)
- prophylactic lithium (1)
- psychological distress (1)
- psychosocial stress (1)
- psychotropic medication (1)
- psychotropic medications (1)
- reliability (1)
- remitted/acute phase (1)
- risk genes (1)
- self-employed (1)
- small business (1)
- stress (1)
- substance abuse disorder (1)
- tandem mass spectrometry (1)
- therapy response (1)
- venturesomeness (1)
- verbal n-back (1)
Institut
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (24)
- Frauenklinik und Poliklinik (2)
- Institut für Klinische Epidemiologie und Biometrie (2)
- Lehrstuhl für Molekulare Psychiatrie (2)
- Neurologische Klinik und Poliklinik (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (1)
Sonstige beteiligte Institutionen
Anxious depression represents a subtype of major depressive disorder and is associated with increased suicidality, severity, chronicity and lower treatment response. Only a few studies have investigated the differences between anxious depressed (aMDD) and non-anxious depressed (naMDD) patients regarding treatment dosage, serum-concentration and drug-specific treatment response. In our naturalistic and prospective study, we investigated whether the effectiveness of therapy including antidepressants (SSRI, SNRI, NaSSA, tricyclics and combinations) in aMDD patients differs significantly from that in naMDD patients. In a sample of 346 patients, we calculated the anxiety somatization factor (ASF) and defined treatment response as a reduction (≥50%) in the Hamilton Depression Rating Scale (HDRS)-21 score after 7 weeks of pharmacological treatment. We did not observe an association between therapy response and the baseline ASF-scores, or differences in therapy outcomes between aMDD and naMDD patients. However, non-responders had higher ASF-scores, and at week 7 aMDD patients displayed a worse therapy outcome than naMDD patients. In subgroup analyses for different antidepressant drugs, venlafaxine-treated aMDD patients showed a significantly worse outcome at week 7. Future prospective, randomized-controlled studies should address the question of a worse therapy outcome in aMDD patients for different psychopharmaceuticals individually.